Abstract:Drug-induced torsade de pointes (TdP) is a life-threatening ventricular arrhythmia responsible for the withdrawal of many drugs from the market. Although currently used TdP risk-assessment methods are effective, they are expensive and prone to produce false positives. In recent years, in silico cardiac simulations have proven to be a valuable tool for the prediction of drug effects. The objective of this work is to evaluate different biomarkers of drug-induced proarrhythmic risk and to develop an in silico risk classifier. Cellular simulations were performed using a modified version of the O'Hara et al. ventricular action potential model and existing pharmacological data (IC50 and effective free therapeutic plasma concentration, EFTPC) for 109 drugs of known torsadogenic risk (51 positive). For each compound, four biomarkers were tested: Tx (drug concentration leading to a 10% prolongation of the action potential over the EFTPC), TqNet (net charge carried by ionic currents when exposed to 10 times the EFTPC with respect to the net charge in control), Ttriang (triangulation for a drug concentration of 10 times the EFTPC over triangulation in control), and TEAD (drug concentration originating early afterdepolarizations over EFTPC). Receiver operating characteristic (ROC) curves were built for each biomarker to evaluate their individual predictive quality. At the optimal cutoff point, accuracies for Tx, TqNet, Ttriang, and TEAD were 89.9, 91.7, 90.8, and 78.9% respectively. The resulting accuracy of the hERG IC50 test (current biomarker) was 78.9%. When combining Tx, TqNet and Ttriang into a classifier based on decision trees, the prediction improves, achieving an accuracy of 94.5%. The sensitivity analysis revealed that most of the effects on the action potential are mainly due to changes in IKr, ICaL, INaL and IKs. In fact, considering that drugs affect only these four currents, TdP risk classification can be as accurate as when considering effects on the seven main currents proposed by the CiPA initiative. Finally, we built a ready-to-use tool (based on more than 450 000 simulations), which can be used to quickly assess the proarrhythmic risk of a compound. In conclusion, our in silico tool can be useful for the preclinical assessment of TdP-risk and to reduce costs related with new drug development. The TdP risk-assessment tool and the software used in this work are available at <a class="extLink" href="https://riunet.upv.es/handle/10251/136919">https://riunet.upv.es/handle/10251/136919</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00201?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00201</a>.Equations of the activation (mss) and inactivation gates (hss, hssp, and jss) at the steady state of the rapid Na+ current in the O'Hara et al. model and in the modified version. IC50 values (nM), Hill coefficients, and effective free therapeutic plasma concentration (EFTPC) (nM) used to simulated the 109 drugs studied in this work. Performance of the four arrhythmogenic biomarkers depending on the currents on which the effect of the drug is assumed: the seven CiPA currents; IKr, ICaL, and IKs, or, IKr, ICaL, and INaL. Performance of the classifiers depending on the biomarkers used as inputs. Results of the sensitivity analysis with the multiple linear regression method. Results of the sensitivity analysis applying the PLS method. Decision trees that constitute the binary TdP risk classifier based on Tx, TqNet, and Ttriang (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00201/suppl_file/ci0c00201_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

GW24-e2999 Proarrhythmic window of a drug determines the risk of multiple ion channel inhibitors

Proarrhythmic and Antiarrhythmic Effects of Multiple Ion Channel Inhibitors Modulated by the Late Sodium Current

Abstract 14727: Late Sodium Current Plays a Role in Ventricular Arrhythmias Associated with Increased Intracellular Calcium Concentration

Proarrhythmic Potential of Low-risk Drugs That Affect the Ventricular Repolarization

Effect of Ivabradine Prolonging the Cardiac Action Potential Duration With its Proarrhythmic Action in Experimental Rabbitin vitro

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Mechanisms underlying arrhythmogenesis in long QT syndrome

Effects of inhibition of endogenous late sodium current on the reverse rate dependence and transmural dispersion of action potential duration prolongation by drugs that inhibit potassium currents

Classification of antiarrhythmic agents: electropharmacologic basis and clinical relevance

Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects

Theoretical possibilities for the development of novel antiarrhythmic drugs

Development of a Patient-Specific P.d85n-Potassium Voltage-Gated Channel Subfamily E Member 1–induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for Drug-Induced Long QT Syndrome

Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance

Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium

In Silico Classifiers for the Assessment of Drug Proarrhythmicity

Inhibition of Late Sodium Current Suppresses Calcium-Related Ventricular Arrhythmias by Reducing the Phosphorylation of CaMK-II and Sodium Channel Expressions

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy

Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone

Effects of the Late Sodium Current Inhibitor on the Interatrial Conduction Time and Acetylcholine-Induced Atrial Fibrillation

Machine learning in drug development: Characterizing the effect of 30 drugs on the QT interval using Gaussian process regression, sensitivity analysis, and uncertainty quantification

A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics